AbbVie, Gilgamesh sign potential $2B deal to develop next-gen psychedelics for psychiatric disorders
Gilgamesh’s pipeline is powered by its proprietary drug discovery platform, which combines “complex behavioral assessments, advanced electrophysiology and molecular measures of neuroplasticity” to identify and design novel drugs, according to the biotech’s website.